Even for an industry that depends on relentless innovation to thrive, life sciences have seen remarkable advancements in recent decades. From the Human Genome Project paving the way for precision ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with Cambridge, ...

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes, making it easier to receive treatment, whilst also reducing risks like ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results presented at the San Antonio Breast Cancer Symposium (SABCS) ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in a phase 3 trial, although the drugmaker thinks it has seen signs of ...

Join our exploration of vital oncology topics, including caring for cancer survivors, AI in patient care, the future of CAR-T therapies, and the rise of targeted radiopharmaceuticals. Plus, discover ...

Hengrui Pharma and partner Kailera have joined the ranks of companies with clinical data in hand for an oral drug for weight loss, reporting weight loss of up to 12.1% in a phase 2 trial with their ...

Good Clinical Practice (GCP), the bedrock of ethical and high-quality clinical research, guides operations among sponsor companies, contract research organisations (CROs), investigator sites, and ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...

Novo Nordisk is already facing competition for its new oral formulation of weight-loss drug Wegovy, after telehealth company Hims & Hers started selling a cut-price, compounded version. The US ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials. The good news is that ...